Preventive treatment: protect your baby against Bronchiolitis
From October 1 to November 1, 2024, specific consultation slots will be available at Children’s Hospital and Erasme Hospital to welcome parents and their babies. These appointments are specifically designed to facilitate easy access to preventive treatment for bronchiolitis, ensuring that families receive quick and efficient care as part of the national prevention campaign. Book your appointment today!
Practical Information for Parents:
- Specific slots for administering Beyfortus to babies will be available.
- For babies born between April 1 and October 1, 2024, it is necessary to book an appointment with the general pediatrics department.
- This preventive treatment will be administered in October and provides five months of protection against bronchiolitis caused by the Respiratory Syncytial Virus (RSV).
How to Book an Appointment:
- At Erasme Hospital (Anderlecht): 02 555 31 11 or Book an appointment here
- At Children's Hospital (Jette): 02 477 33 11 or Book an appointment here
Bronchiolitis: A Public Health Concern
Bronchiolitis affects many babies each year. While it is often mild, it can occasionally lead to severe complications requiring hospitalization. This campaign, timed for the winter months when the virus circulates most, aims to reduce severe cases and alleviate pressure on healthcare services.
An Innovative Treatment: Beyfortus™ (Nirsevimab)
The cornerstone of this campaign is Beyfortus™ (Nirsevimab), a monoclonal antibody that provides fast and long-lasting protection against RSV. A single dose is sufficient to protect infants for five months, covering the entire viral season.
Administration Details:
- Babies born after October 1, 2024: The antibody will be administered directly in the maternity ward.
- Babies born between April 1 and October 1, 2024: Administration will occur in the pediatrics departments of Erasme and HUDERF hospitals.
The Importance of This Initiative
As winter approaches, this campaign is crucial for preventing infection waves, reducing hospital admissions, and providing optimal protection for vulnerable infants.
Safety and Efficacy
Clinical studies show that Beyfortus reduces the risk of bronchiolitis by 70 to 80%, including in severe cases requiring hospitalization. Side effects have been rare and mild, bolstering confidence in this preventive treatment.